Equity · Healthcare
GPCR
NASDAQStructure Therapeutics (GPCR)
The line runs 35 USD on 18 September through 21.17 USD on 23 October, on a scale from 20 to 40. Days the market did not trade hold the previous close, flat.
- Market cap
- 4.5B USD
- EPS, diluted, year to Dec 2025
- −0.80 USD
- Avg volume
- 77.6K
as of Oct 23, 2026
Have Structure Therapeutics (GPCR) insiders bought or sold shares recently?
In the 90 days to 22 Nov 2026, no Structure Therapeutics insider bought or sold shares on the open market; all 4 Form 4 filings in that window were grants, exercises, tax withholding or transfers (SEC Form 4).
Form 4, 90 days to 22 Nov 2026, newest Form 4 filing 21 Sep 2026
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 21 Sep 2026 | Coll Crespo BlasCHIEF MEDICAL OFFICER | Other | 12,024 | |
| 18 Sep 2026 | Coll Crespo BlasCHIEF MEDICAL OFFICER | Tax withheld | 10,626 | 124K USD |
| 01 Sep 2026 | Lin XichenCHIEF SCIENTIFIC OFFICER | Option exercise | 17,817 | 6K USD |
| 01 Sep 2026 | Lin XichenCHIEF SCIENTIFIC OFFICER | Other | 17,817 |
Which funds hold Structure Therapeutics (GPCR)?
7 of the 45 institutional funds we track reported a Structure Therapeutics position for the quarter ended 30 Sep 2026 — a combined 72.2M USD; the latest of those filings landed 16 Nov 2026.
| Fund | Position | Shares | Value | Shares q/q |
|---|---|---|---|---|
| Baker Bros. Advisors | Held (±25%) | 1,432,529 | 44.8M USD | |
| Two Sigma Investments | Added | 442,107 | 13.8M USD | +116.6% |
| Citadel Advisors | New position | 116,295 | 3.6M USD | |
| D. E. Shaw & Co. | Held (±25%) | 115,300 | 3.6M USD | |
| Marshall Wace | Trimmed | 108,366 | 3.4M USD | −59.5% |
| Millennium Management | Held (±25%) | 80,675 | 2.5M USD | −9.9% |
| Tudor Investment Corp | Trimmed | 12,639 | 395K USD | −76.4% |
What has been filed or recorded for Structure Therapeutics (GPCR)?
The filings we hold for Structure Therapeutics, newest first: 4 fails-to-deliver days, 6 quarterly earnings reports, 2 annual reports and 4 reported financial figures, the latest dated 20 Oct 2026. No next earnings date is announced in SEC filings yet.
| And | ||||
|---|---|---|---|---|
| 20 Oct 2026 | Fails to deliver | Shares failed to deliver | 42,724 shares | 940K USD notional · 0.020% of shares out |
| 14 Oct 2026 | Fails to deliver | Shares failed to deliver | 3,299 shares | 74K USD notional · 0.002% of shares out |
| 13 Oct 2026 | Fails to deliver | Shares failed to deliver | 912 shares | 22K USD notional · <0.001% of shares out |
| 09 Oct 2026 | Fails to deliver | Shares failed to deliver | 30 shares | 770 USD notional · <0.001% of shares out |
| 30 Sep 2026 | Quarterly earnings | Q3 2026 reported | EPS −0.66 USD | |
| 30 Sep 2026 | Financials | Total assets | 1.3B USD | at period end |
| 30 Sep 2026 | Financials | Total equity | 1.2B USD | at period end |
| 30 Jun 2026 | Quarterly earnings | Q2 2026 reported | EPS −0.49 USD | |
| 31 Mar 2026 | Quarterly earnings | Q1 2026 reported | EPS −0.35 USD | |
| 31 Dec 2025 | Annual report | FY 2025 reported | EPS −0.80 USD | |
| 31 Dec 2025 | Financials | Net income | −141.2M USD | fiscal year |
| 31 Dec 2025 | Financials | Diluted EPS | −0.80 USD | fiscal year |
| 30 Sep 2025 | Quarterly earnings | Q3 2025 reported | EPS −0.37 USD | |
| 30 Jun 2025 | Quarterly earnings | Q2 2025 reported | EPS −0.36 USD | |
| 31 Mar 2025 | Quarterly earnings | Q1 2025 reported | EPS −0.27 USD | |
| 31 Dec 2024 | Annual report | FY 2024 reported | EPS −0.78 USD |
What do people ask about Structure Therapeutics (GPCR)?
What did Structure Therapeutics shares close at?21.17
Structure Therapeutics closed at 21.17 USD on 23 Oct 2026, down 3.66% on the close before. That is the end-of-day price from Finazon, not a live quote.
What is Structure Therapeutics’ market cap?4.5B
Structure Therapeutics is worth 4.5B USD by market value as of 23 Oct 2026, which is the share price times the shares on issue from its SEC filings.
Have Structure Therapeutics insiders bought or sold shares recently?4 filings
In the 90 days to 22 Nov 2026, no Structure Therapeutics insider bought or sold shares on the open market; all 4 Form 4 filings in that window were grants, exercises, tax withholding or transfers (SEC Form 4). See Insiders
Which funds own Structure Therapeutics?7 of 45
7 of the 45 funds we track reported a Structure Therapeutics position for the quarter ended 30 Sep 2026, per their SEC Form 13F filings. The largest reported positions were Baker Bros. Advisors, Two Sigma Investments and Citadel Advisors. See Funds
When did Structure Therapeutics last report earnings?−0.66
Structure Therapeutics last reported earnings on 30 Sep 2026 for Q3 2026, with EPS of −0.66 USD; no next date is announced in SEC filings yet. See Filings

Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.
References
- Finazonprior-day close, indicative (IEX-derived, not the official close), some closes dollar-rounded at the source
- TradingViewthe price chart widget, drawn by TradingView from their own data
- SEC EDGARForm 4 filings (insider transactions)
- SEC EDGAR13F filings
- SECSEC fails-to-deliver (CNS) data
- SEC EDGARXBRL company facts, latest period ended 30 Sep 2026
- SEC EDGARreported earnings figures and scheduled report dates
- SEC EDGARValuation computed from SEC EDGAR filings
- SEC filingAbout text: the company's latest annual report filed with the SEC (Business section), summarised in our own words